Veeva price target raised to $195 from $183 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Veeva (VEEV) to $195 from $183 and keeps an Underweight rating on the shares. Diversified Managed Care “woefully underperformed” in 2024 and while uncertainty is pressuring sentiment, the firm sees “opportunities in a friendlier policy backdrop,” the analyst tells investors in a 2025 outlook note on the healthcare services group. Among Healthcare Technology and Providers, the firm remains selective due to mixed demand and policy uncertainties, the analyst added.